Premium
P3‐289: Complementary benefit of memantine and donepezil on activities of daily living by disease stage when used together: Post hoc analysis of two trials in moderate to severe Alzheimer's disease
Author(s) -
Hendrix Suzanne,
Ellison Noel,
Otcheretko Victor
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.06.1662
Subject(s) - donepezil , memantine , placebo , post hoc analysis , medicine , context (archaeology) , psychology , randomized controlled trial , pharmacology , disease , anesthesia , dementia , pathology , paleontology , alternative medicine , biology
modulation may be easily achieved with the repurposing of existing and readily available agents with HDACI properties, like VPA. While VPA has failed to influence clinical outcomes in subjects with moderate to severe AD, its use as a safe and effective HDACI suggest it may still have a role in modulation of AD risk. Further clinical studies of HDACI (VPA or others), in subjects not homozygous for the CLU minor allele, for the prevention of AD are warranted.